MonobenzoneMonobenzone
MedChemExpress (MCE)
HY-30272
103-16-2
99.93%
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Room temperature in continental US
may vary elsewhere.
Monobenzone is a potent skin depigmenting agent. Monobenzone induces depigmentation and exhibits good potential for vitiligo research. Monobenzone is a potent inhibitor of RNR (Ribonucleotide reductase) enzyme activity by targeting RRM2 (a regulatory small subunit M2 of RNR) protein, and thus has significant anti-leukemia efficacy in vitro and in vivo. Monobenzone inhibits acute myeloid leukemia (AML) cells proliferation and DNA synthesis, induces cell cycle arrest, and Apoptosis .
Monobenzone (2.5- 40 μM, 24-48 h) inhibits AML cells proliferation with IC50s of 6-18 μM and causes dose dependent DNA synthesis inhibition, induces cell cycle arrest and apoptosis in KG-1A, MOLM13, NB4 cells[2]. Monobenzone (0-10 μM, 24-48 h) blocks DNA damage repair in KG-1A, MOLM13, NB4 cells[2]. Monobenzone (0-100 μM, 72 h) overcomes the drug resistance to Ara-C (Cytarabine (HY-13605)), DOX (Doxorubicin(HY-15142)) and HU (Hydroxyurea(HY-B0313)) in KG-1A-ARAC, KG-1A-DOX, and KG-1A-HU cells[2]. Monobenzone (0-100 μM, 72 h) with the Bcl-2 inhibitor ABT-737 (HY-50907) synergistically inhibits cell the growth with an IC50 of 2.52 μM in MOLM13 cells and an IC50 of 9.69 μM in KG-1A cells compared with monobenzone alone[2].
Monobenzone (40%, 60% cream, daily, 30-50 days) induces skin depigmentation on the non exposed sites and that the severity of lesions depends on drug dosage in C57BL/6 mice [1]. Monobenzone (100 - 200 mg/kg, i.p., daily, 2 weeks) effectively inhibits AML cell (MOLM13 cells) xenograft growth in nude mice [2].
| | | |
| | | | | |
[1]. Zhu Y, et al. A mouse model of vitiligo induced by monobenzone. Exp Dermatol. 2013 Jul
22(7):499-501. doi: 10.1111/exd.12184. [Content Brief]
[2]. Dong J, et al. Identification of Monobenzone as a Novel Potential Anti-Acute Myeloid Leukemia Agent That Inhibits RNR and Suppresses Tumour Growth in Mouse Xenograft Model. Cancers (Basel). 2022 Sep 27
14(19):4710. [Content Brief]